- In adult patients co-infected with genotype 1 (GT1) hepatitis C virus (HCV)
and human immunodeficiency virus type 1 (HIV-1), TURQUOISE-I, using VIEKIRA
PAK with ribavirin (RBV), demonstrated sustained virologic response rates 12
weeks post-treatment (SVR12) of 94 percent with 12 weeks of treatment and 91
percent with 24 weeks of treatment, respectively
- TURQUOISE-I results published online today in The Journal of the American
Medical Association (JAMA)
- Additional sub-analyses of TURQUOISE-I data to be presented this week at the
Annual Conference on Retroviruses and Opportunistic Infections (CROI)
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in